Atrasentan Provides Clinically Meaningful Proteinuria Reduction in Patients with IgAN Receiving Optimized Standard-of-Care

Atrasentan Provides Clinically Meaningful Proteinuria Reduction in Patients with IgAN Receiving Optimized Standard-of-Care

Treatment with atrasentan resulted in clinically meaningful reductions in proteinuria at weeks 6, 12 and 24 in patients with IgAN already on a maximally tolerated and stable dose of a RAS inhibitor

Format

PNG

Source

Chinook Therapeutics, Inc.

Downloads